<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="321">
  <stage>Registered</stage>
  <submitdate>29/08/2005</submitdate>
  <approvaldate>6/09/2005</approvaldate>
  <actrnumber>ACTRN12605000317695</actrnumber>
  <trial_identification>
    <studytitle>The clinical significance of heterogeneity in asthma</studytitle>
    <scientifictitle>The clinical significance of ventilation heterogeneity in asthma, before and after 3 months of inhaled corticosteroid treatment</scientifictitle>
    <utrn />
    <trialacronym>02AU02-Bron trial</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Asthmatics were assigned to either Respocort or QVAR treatment for the duration of 3 months.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Ventilation heterogeneity</outcome>
      <timepoint>Measured at baseline, and then at 1, 2 and 3 months during treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Airway hyper-responsiveness</outcome>
      <timepoint>Measured at baseline, and then at 1, 2 and 3 months during treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Exhaled nitric oxide</outcome>
      <timepoint>Measured at baseline, and then at 1, 2 and 3 months during treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung function (spirometry and body plethysmography)</outcome>
      <timepoint>Measured at baseline, and then at 1, 2 and 3 months during treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory system resistance</outcome>
      <timepoint>Measured at baseline, and then at 1, 2 and 3 months during treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cough sounds and respiratory symptoms. </outcome>
      <timepoint>Measured at baseline, and then at 1, 2 and 3 months during treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Doctor-diagnosed asthma, with symptoms in the last 12 months.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current smoking (in the last 6 months)* &gt; 10 pack year history of smoking* Any other lung disease* Oral prednisone use in the last 4 weeks* Respiratory tract infection in the last 4 weeks.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The sequence was concealed and allocated by hospital pharmacy.</concealment>
    <sequence>The random number sequence was generated by the random number generator in Microsoft Excel. The restriction method was by blocking.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>27/06/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>47</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Central Sydney Area Health Service</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>CRC for Asthma</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Woolcock Institute of Medical Research</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ms Sue Downie</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95157524</phone>
      <fax>+61 2 95506115</fax>
      <email>sued@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Wendy Taylor</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>wtaylor@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>